Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study |
| |
| Affiliation: | 1. Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai, China;2. Department of Medical Oncology, Hunan Cancer Hospital, Hunan, China;3. Department of Medical Oncology, Baotou Cancer Hospital, Baotou, China;4. Department of Medical Oncology, The 900th Hospital of People’s Liberation Army, Fuzhou, China;5. Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China;6. Department of Medical Oncology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;7. Department of Medical Oncology, The Third Hospital of Zhengzhou, Zhengzhou, China;8. Department of Medical Oncology, Zhejiang Rongjun Hospital, Jiaxing, China;9. Department of Pathology, Fujian Cancer Hospital, Fujian Medical University, Fujian, China;10. Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Banshan National Park Forest, China;11. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China |
| |
| Abstract: | BackgroundRearranged during transfection (RET) proto-oncogene gene fusions are rare in non–small-cell lung cancer (NSCLC). We compared the efficacy of pemetrexed-based chemotherapy with other chemotherapy regimens in patients with NSCLC with different RET fusion subtypes.Patients and MethodsA retrospective, multicenter study of patients with pathologically confirmed stage IIIB/IV lung adenocarcinomas was conducted. RET rearrangements were detected using next generation sequencing. We analyzed the clinical characteristics of patients with RET-rearranged NSCLC and the efficacy of chemotherapy regimens. We also evaluated the efficacy between groups of patients with and without KIF5B-RET–rearranged lung cancer.ResultsWe evaluated 62 patients with NSCLC and RET rearrangements, including 41 with KIF5B-RET, 15 with CCDC6-RET, and 6 with other rare fusion subtypes. Of these 62 patients, 50 had stage IIIB/IV. We also evaluated 40 patients with first-line chemotherapy information available. The median progression-free survival was significantly different between those receiving pemetrexed-based chemotherapy and those receiving other chemotherapy regimens (9.2 vs. 5.2 months; P = .007). The median progression-free survival for patients with KIF5B-RET fusion and non–KIF5B-RET fusion was not significantly different statistically (7.8 vs. 11.2 months; P = .847). For second-line chemotherapy, a statistically significant difference was found between the chemotherapy regimens (4.9 vs. 2.8 months; P = .049). Survival follow-up data were available for 38 patients with advanced NSCLC. The median overall survival was 26.4 months. The overall survival of the patients with RET-rearranged NSCLC who had received pemetrexed-based chemotherapy versus no pemetrexed-based chemotherapy was 35.2 versus 22.6 months (P = .052). No difference in survival was observed between the patients with KIF5B-RET and non–KIF5B-RET rearrangements.ConclusionsPemetrexed-based treatment should be considered first when selecting the chemotherapy regimen for patients with NSCLC and RET rearrangements. |
| |
| Keywords: | Chemotherapy regimens Non–small-cell lung cancer RET rearrangement Survival Treatment |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
